MedTrace Logo

Combination CurQD and Vedolizumab in Ulcerative Colitis

NCT07665294 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-07-27

No results posted yet for this study

Summary

The purpose of this research study is to test the efficacy and safety of the study intervention, CurQD or placebo (non-active pill), in combination with vedolizumab prescribed as standard of care for patients with ulcerative colitis (UC)..

Conditions

Interventions

DRUG

CurQD

Capsule doses 235mg - 385mg curcumin/150mg-300mg QingDai

DRUG

Placebo

Matching capsules

DRUG

Vedolizumab

as prescribed by participant's provider as part of routine clinical care

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Ryan C Ungaro

    lead OTHER

Principal Investigators

  • Ryan Ungaro, MD MS · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2027-06-23
Completion
2027-06-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07665294 on ClinicalTrials.gov